Em recrutamento
FASE
Número Europeu 2022-501489-24-00
KT-US-484-0136 / ZUMA-23
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-23)
Detalhes
Destaques